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ously, and just assumed to result from the inability of a degenerating
neuron to properly distribute its proteins. In 2010, tau was show to be
normally synthesized in the somatodendritic compartment,where it ac-
tively accumulates during stress, instead of shuttling to the axon
(Hoover et al. 2010; Li et al. 2011). The presence of tau mRNA in theIn this issue of EBioMedicine, Kobayashi et al. demonstrate the pres-
ence of taumRNA in the dendritic bouton, and induction of dendritic tau
translation and phosphorylation following stimulation of the ionotropic
(NMDA & AMPA) glutamate receptors (Kobayashi et al. 2017). This
work, emanating from the laboratory of Akihiko Takashima, adds an im-
portant chapter to the accumulating evidence demonstrating an active
role for tau in the biology of the dendritic bouton and synaptic signaling.
Under normal conditions, the vast majority of tau exists in the axon.
Thismeans that bulk analysis of tau proteinwill largely reﬂect the prop-
erties of axonal tau. However, it is now clear that tau also functions in
neuronal domains other than the axon. Ittner and colleagues demon-
strated that tau protein exists in the dendrite and moves into the den-
dritic bouton with glutamatergic stimulation (Ittner et al. 2016).
Dendritic tau is responsive to phosphorylation by Fyn and by PKCγ
(Ittner et al. 2016). The current work from Takashima's group brings
GSK3β into the picture as an additional regulator of dendritic tau, phos-
phorylating S202, which is adjacent to the site phosphorylated by PKCγ,
at S205. In each case, phosphorylation of tau is stimulated by activation
of theNMDA receptor, signaling via calcium. Takashima's group extends
the story further by using the protein synthesis inhibitor cycloheximide
to demonstrate that NMDAR and AMPAR activation also leads to stimu-
lation of tau translation in the dendritic bouton. The coupling of initia-
tion of tau translation with stimulation of tau phosphorylation
provides an important independent means of conﬁrmation of the role
of tau in post-synaptic activity. Thus, the evidence demonstrating a
role for tau in dendritic synaptic activity now includes evidence at
both protein and mRNA levels.
The somatodendritic localization of tau has been apparent since tau
was ﬁrst shown to be the major component of neuroﬁbrillary tangles, am.2017.05.012.
. This is an open access article underpathological hallmark of Alzheimer's disease, in the 1980′s. The reason
for localization of tau away from the axon was rarely questioned previ-
soma provides a strong basis for the presence of tau in the dendritic
arbor; one only need to invoke trafﬁcking by RNA transport granules
containing RNA binding proteins (RBPs). The current report by
Kobayashi et al. demonstrate colocalization of tau mRNA with two
RBPs, stau1 and FMRP, that function as transport proteins.
The role of RBPs in tau biology turns out to be profoundly important.
All RNA is trafﬁcked throughout the neuron in neuronal trafﬁcking gran-
ules that are composed of RNA binding proteins and mRNA. These RBPs
then appear to exhibit a natural tendency to coalescence into a state re-
sembling lipid droplets or vesicles, except there is no lipid
present(Alberti andHyman 2016). Rather, the proteins themselves con-
tain low complexity domains that tend to reversibly “aggregate”, which
allows the RBP/RNA complexes to form granules, which can be consid-
ered to be membraneless organelles. These membraneless organelles
appear to form through a process termed liquid-liquid phase separation,
and enable the organization of many structures in the cell, such as the
nucleolus, P bodies, transport granules, nuclear speckles and possible
even transcription complexes. Stress granules constitute another class
of RNA granule. These granules are also RBP/RNA complexes that se-
quester non-essential mRNA during stressful conditions, allowing the
cell to direct protein synthesis towards cytoprotective proteins. (Ash
et al. 2014; Panas et al. 2016). It's easy to imagine that stress granules
are important for disease, which are characterized by persistent stress;
mutations in RBPs that increase the tendency of these proteins to aggre-
gate cause ALS and myopathies, possibly because of persistent stress
granules that become pathological.
Tau was recently shown to participate in stress granule biology, and
persistence of stress granules stimulates tau aggregation (Vanderweyde
et al. 2016). RNA binding proteins are present in neuroﬁbrillary pathol-
ogy inmousemodels of tauopathy and in human cases of tauopathy, in-
cludingAlzheimer's disease (Vanderweyde et al. 2016). Persistent stress
granules directly stimulate tau aggregation and tau stimulates stress
granules, indicating that the biology is bi-directional. Indeed, stimula-
tion of stress granule formation appears to be an important biological
function of tau. These accumulating data combined with the recent
work by Kobayashi et al., the “mislocalization” of tau to thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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as a pathological mistake.
The cumulative impact of all of these studies broadens our percep-
tion of the roles of tau in biology and disease. It is now apparent that
tau exists in many different domains within the neuron, and the func-
tion of tau varies depending on the neuronal domain being considered.
The expanding biology of tau is apparent in recent studies demonstrat-
ing that tau knockout impairs synaptic plasticity and interferes with
neuronal and behavioral response to stress (Lopes et al. 2016). A re-
duced stress response dampens the toxicity of Aβ but might also leave
the neuron less able to cope with other types of stress (Vossel et al.
2010). Managing the excessive tau-directed stress response in AD and
other tauopathies might end up being analogous to treatment of hyper-
tension where the therapeutic goal is to reduce persistently high blood
pressure, but not eliminate blood pressure. In the sameway, the goal for
treating neurodegenerative disease might be to reduce a persistently
hyperactive translational stress response without eliminating the stress
response.Conﬂicts of Interest Statement
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